KR930021143A - 안정한 포르피머 나트륨 조성물 및 그의 제조방법 - Google Patents

안정한 포르피머 나트륨 조성물 및 그의 제조방법 Download PDF

Info

Publication number
KR930021143A
KR930021143A KR1019930007074A KR930007074A KR930021143A KR 930021143 A KR930021143 A KR 930021143A KR 1019930007074 A KR1019930007074 A KR 1019930007074A KR 930007074 A KR930007074 A KR 930007074A KR 930021143 A KR930021143 A KR 930021143A
Authority
KR
South Korea
Prior art keywords
composition
porphyrin
less
sodium hydroxide
sodium
Prior art date
Application number
KR1019930007074A
Other languages
English (en)
Other versions
KR100221206B1 (ko
Inventor
엘. 클라우드 스티븐
제이. 파스텔 마이클
케이. 자와즈키 레이너
Original Assignee
케니드 갈브레이드
콰드라 로직 테크놀로지스 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케니드 갈브레이드, 콰드라 로직 테크놀로지스 인코오퍼레이티드 filed Critical 케니드 갈브레이드
Publication of KR930021143A publication Critical patent/KR930021143A/ko
Application granted granted Critical
Publication of KR100221206B1 publication Critical patent/KR100221206B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

암 또는 다른 조건의 광역학적 치료에 유용한 저장안정성 포르피머 나트륨(폴리 헤마토포르피린 에테르/에스테르)조성물이 제공되어 있다. 조성물은 에스테르 결합 포르피린 올리고머의 백분율이 조성물의 10%이하인 것을 특징으로 한다.
그러한 조성물의 개선된 제조방법이 또한 제공되어 있으며, 거기에서 아세틸화 해마토 포르피린은 에스테르결합에 의해 연결된 포르피린 올리고머의 양을 조성물의 10%이하로 감소시키는 온도에서 충분한 시간동안 알칼리로 처리된다.

Description

안정한 포르피머 나트륨 조성물 및 그의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
내용없음

Claims (8)

  1. 에테르 및 에스테르 공유 결합을 지는 포르피린 올리고머와 약학적으로 허용된 담체로 이루어진 포르피머 나트륨 약한 조성물에 있어서, 포르피머 올리고머10%이하가 에스테르 결합에 의해 연결되어 있는 것을 특징으로 하는 조성물.
  2. 형광을 띠고 감광작용을 하며 정상조직에 비해 종양조직에 집중되어 존재하고 포르피린 올리고머의 혼합물, 및 그의 약학적으로 허용된 염으로 이루어진 생물학적 활성 조성물에 있어서, 상기 올리고머는 에테르 및 에스테르결합에 의해 공유결합된 2~8개의 포르피린 분자로 이루어지고, 적어도 1개의 포르피린 분자는 식;
    을 지니며, 상기식에서 R은 히드록시에틸 또는 비닐이고 나타낸 결합은 상기 공유결합을 형성하고, 상기 조성물중 에스테르 결합의 백분율은 조성물10%이하인 것을 특징으로 하는 조성물.
  3. 에테르 및 에스테르 결합을 지니는 포르피린 올리고머로 이루어진 포리피머 나트륨 약학 조성물의 제조방법에 있어서, 에스테르 결합에 의해 연결된 포리피린 올리고머의 양을 조성물의 10%이하로 감소시키기에 충분한 온도에서 아세틸화 헤마토포르피린을 충분한 시간동안 알칼리로 처리하는것을 포함하는 것을 특징으로 하는방법.
  4. 제3항에 있어서, 알칼리는 수산화 나트륨인 것을 특징으로 하는 방법.
  5. 아세틸화 헤마토포르피린과 수산화 나트륨의 반응을 이용한 포르피머 나트륨 조성물의 제조방법에 있어서, 아세틸화 헤마토포르피린을 적어도 1시간동안 0. 1N 수산화 나트륨과 접촉시키는것, 용액을 4℃에서 14내지 21시간동안 저장하는것, 및 투석여과로 정제하는 것이 개선점인 것을 특징으로 하는 방법.
  6. 아세틸화 헤마토포르피린과 수산화 나트륨의 반응을 이용한 포르피머 나트륨 조성물의 제조방법에 있어서, 아세틸화 헤마토포르피린을 적어도 0.1N 수산화 나트륨과 45℃이하의 온도에서 16내지 24시간동안 접촉시키는것, 및 45℃이하의 온도에서 투석여과를 통해 정제하는 것이 개선점인 것을 특징으로 하는 방법.
  7. 아세틸화 헤마토포르피린과 수산화 나트륨의 반응을 이용한 포르피머 나트륨 조성물의 제조방법에 있어서, 아세틸화 헤마토포르피린을 0.1N 수산화 나트륨과 적어도 1시간동안 접촉시키는 것, 농도를 적어도 0.2N 내지 1N미만으로 2내지 24시간동안 증가시키는것. 및 실온에서 투석여과로 정제하는 것이 개선점인 것을 특징으로 하는 방법.
  8. 제3항, 제4항, 제5항, 제6항 또는 제7항의 방법으로 제도된 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930007074A 1992-04-27 1993-04-27 안정한 포르피머 나트륨 조성물 및 그의 제조방법 KR100221206B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/873,860 US5244914A (en) 1992-04-27 1992-04-27 Stable porfimer sodium compositions and methods for their manufacture
US7/873,860 1992-04-27

Publications (2)

Publication Number Publication Date
KR930021143A true KR930021143A (ko) 1993-11-22
KR100221206B1 KR100221206B1 (ko) 1999-10-01

Family

ID=25362473

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930007074A KR100221206B1 (ko) 1992-04-27 1993-04-27 안정한 포르피머 나트륨 조성물 및 그의 제조방법

Country Status (10)

Country Link
US (2) US5244914A (ko)
EP (1) EP0568323B1 (ko)
JP (1) JP2928047B2 (ko)
KR (1) KR100221206B1 (ko)
AT (1) ATE150968T1 (ko)
CA (1) CA2094974C (ko)
DE (1) DE69309340T2 (ko)
DK (1) DK0568323T3 (ko)
ES (1) ES2104056T3 (ko)
GR (1) GR3023978T3 (ko)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US7097826B2 (en) 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US6534040B2 (en) 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7078014B2 (en) * 1999-12-23 2006-07-18 Health Research, Inc. Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20060052286A1 (en) * 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
US20060223750A1 (en) * 2005-04-01 2006-10-05 Allergan, Inc. Agents and methods for enhancing photodynamic therapy
WO2007142132A1 (ja) * 2006-06-02 2007-12-13 Hamamatsu Foundation For Science And Technology Promotion ポルフィリン（ｙ）の多価金属化合物の新規製造方法
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US8551505B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8221480B2 (en) 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8551506B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20110150765A1 (en) 2008-10-31 2011-06-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Frozen compositions and methods for piercing a substrate
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545855B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545856B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8563012B2 (en) 2008-10-31 2013-10-22 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2011057129A2 (en) 2009-11-09 2011-05-12 Allergan, Inc. Compositions and methods for stimulating hair growth
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin
WO2014127243A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
CA3056396A1 (en) 2017-03-14 2018-09-20 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates
KR102182630B1 (ko) 2019-12-19 2020-11-24 김진왕 친환경 스마트 광감작제 및 이를 포함하는 광줄기세포 치료제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4882234A (en) * 1986-11-12 1989-11-21 Healux, Inc. Storage-stable porphin compositions and a method for their manufacture
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US5059619A (en) * 1989-06-14 1991-10-22 Quadra Logic Technologies, Inc. Stable freeze-dried polyhematoporphyrin ether/ester

Also Published As

Publication number Publication date
DE69309340T2 (de) 1997-07-17
DE69309340D1 (de) 1997-05-07
DK0568323T3 (da) 1997-07-07
EP0568323B1 (en) 1997-04-02
CA2094974A1 (en) 1993-10-28
JPH06220062A (ja) 1994-08-09
EP0568323A1 (en) 1993-11-03
ES2104056T3 (es) 1997-10-01
US5438071A (en) 1995-08-01
JP2928047B2 (ja) 1999-07-28
KR100221206B1 (ko) 1999-10-01
GR3023978T3 (en) 1997-10-31
US5244914A (en) 1993-09-14
CA2094974C (en) 1996-10-22
ATE150968T1 (de) 1997-04-15

Similar Documents

Publication Publication Date Title
KR930021143A (ko) 안정한 포르피머 나트륨 조성물 및 그의 제조방법
US4882234A (en) Storage-stable porphin compositions and a method for their manufacture
CA1257202A (en) Porphyrins and cancer treatment
JPS58500480A (ja) 治療上活性な化合物
ATE71375T1 (de) Substituierte 6-fluor-4-oxo-1,4-dihydrochinolin-3-carbonsaeure ; deren derivate; diese verbindung enthaltende pharmazeutische zubereitungen und verfahren zur herstellung dieser verbindungen.
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
ATE270553T1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
KR890017246A (ko) 크로만 유도체
EP1381611A1 (en) Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
ATE152352T1 (de) Pharmazeutische zusammensetzungen zur hemmung der maillardreaktion
JPWO2008102669A1 (ja) 新規な糖連結クロリン誘導体及びその製造方法
WO1990006314A1 (en) Porphyrin compounds and their uses
US4709022A (en) Pheophorbide derivatives and alkaline salts thereof
GB2094142A (en) Injectable solution containing theophylline and a basic amino acid
ES2377002T3 (es) Conjugados covalentes entre los endoperóxidos relacionados con la artemisinina y las proteínas transportadoras de hierro y procedimientos de utilización
DE60100704T2 (de) Porphyrine und verwandte verbindungen
NO961521L (no) Antiarytmiske og kardiobeskyttende substituerte indenoylguanidiner
PT90706A (pt) Processo para a preparacao de derivados de antraciclinas dotados de actividade citostatica
KR870006040A (ko) 치환된 4-플루오로-이소인돌린, 그의 제조방법과 용도 및 이들을 함유하는 제제
SU1684289A1 (ru) Способ получени конъюгатов на основе производного сефарозы
RU2042683C1 (ru) Водно-глицериновый комплекс (2,3-диоксипропил)-ортотитанат гидрохлорид и фармацевтическая гелесодержащая композиция на его основе
KR890000479A (ko) 8α-아실아미노 에르고린, 그것의 제법 및 그것을 함유하는 약학적 조성물
RU94036750A (ru) 1,2-дигидро-2-оксо-3-метилсульфониламинометил-пиридины, способ их получения, содержащие их фармацевтические композиции и способ их получения
Myers et al. Gold Preparations in Therapy.
WO1986005986A1 (en) Process for preparing carcinostatic substance complex

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120423

Year of fee payment: 14

EXPY Expiration of term